X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs WOCKHARDT LTD. - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD WOCKHARDT LTD. LUPIN LTD/
WOCKHARDT LTD.
 
P/E (TTM) x 29.5 -19.3 - View Chart
P/BV x 2.8 2.0 138.1% View Chart
Dividend Yield % 0.6 0.0 31,178.3%  

Financials

 LUPIN LTD   WOCKHARDT LTD.
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
WOCKHARDT LTD.
Mar-18
LUPIN LTD/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,4651,012 144.8%   
Low Rs727532 136.8%   
Sales per share (Unadj.) Rs349.6355.9 98.2%  
Earnings per share (Unadj.) Rs5.6-60.3 -9.2%  
Cash flow per share (Unadj.) Rs29.6-46.8 -63.3%  
Dividends per share (Unadj.) Rs5.000.01 50,000.0%  
Dividend yield (eoy) %0.50 35,206.0%  
Book value per share (Unadj.) Rs300.3257.8 116.5%  
Shares outstanding (eoy) m452.08110.63 408.6%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.12.2 144.6%   
Avg P/E ratio x197.2-12.8 -1,540.3%  
P/CF ratio (eoy) x37.1-16.5 -224.5%  
Price / Book Value ratio x3.63.0 121.9%  
Dividend payout %90.00 -542,272.0%   
Avg Mkt Cap Rs m495,50285,379 580.4%   
No. of employees `00017.06.3 272.5%   
Total wages/salary Rs m28,6479,371 305.7%   
Avg. sales/employee Rs Th9,273.66,295.0 147.3%   
Avg. wages/employee Rs Th1,681.01,498.3 112.2%   
Avg. net profit/employee Rs Th147.4-1,066.3 -13.8%   
INCOME DATA
Net Sales Rs m158,04239,369 401.4%  
Other income Rs m1,5041,202 125.1%   
Total revenues Rs m159,54540,571 393.2%   
Gross profit Rs m31,47518 171,995.1%  
Depreciation Rs m10,8591,495 726.2%   
Interest Rs m2,0442,555 80.0%   
Profit before tax Rs m20,076-2,830 -709.5%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644-3,582 408.8%   
Tax Rs m2,885257 1,122.4%   
Profit after tax Rs m2,513-6,669 -37.7%  
Gross profit margin %19.90 42,844.9%  
Effective tax rate %14.4-9.1 -158.2%   
Net profit margin %1.6-16.9 -9.4%  
BALANCE SHEET DATA
Current assets Rs m122,09533,796 361.3%   
Current liabilities Rs m50,95626,917 189.3%   
Net working cap to sales %45.017.5 257.6%  
Current ratio x2.41.3 190.8%  
Inventory Days Days8579 106.6%  
Debtors Days Days12089 134.4%  
Net fixed assets Rs m129,87639,664 327.4%   
Share capital Rs m904553 163.4%   
"Free" reserves Rs m134,86627,968 482.2%   
Net worth Rs m135,77128,522 476.0%   
Long term debt Rs m64,24521,731 295.6%   
Total assets Rs m263,05481,620 322.3%  
Interest coverage x10.8-0.1 -10,067.5%   
Debt to equity ratio x0.50.8 62.1%  
Sales to assets ratio x0.60.5 124.6%   
Return on assets %1.7-5.0 -34.4%  
Return on equity %1.9-23.4 -7.9%  
Return on capital %3.7-7.7 -48.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,1419,807 541.9%   
Fx outflow Rs m19,3351,789 1,081.0%   
Net fx Rs m33,8078,019 421.6%   
CASH FLOW
From Operations Rs m17,512684 2,558.7%  
From Investments Rs m-14,0736,302 -223.3%  
From Financial Activity Rs m-14,921-7,695 193.9%  
Net Cashflow Rs m-11,482-664 1,729.2%  

Share Holding

Indian Promoters % 46.6 74.5 62.6%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 2.3 491.3%  
FIIs % 31.9 7.7 414.3%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.1 15.4 65.6%  
Shareholders   98,259 67,757 145.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Nov 21, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS